Trials / Completed
CompletedNCT04393753
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
A Phase II, Open Label Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Advanced Unresectable/Metastatic Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Antibody Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | domatinostat in combination with avelumab | domatinostat tablets and avelumab infusion |
Timeline
- Start date
- 2020-10-13
- Primary completion
- 2024-02-26
- Completion
- 2024-02-26
- First posted
- 2020-05-19
- Last updated
- 2024-05-08
Locations
22 sites across 6 countries: Belgium, France, Germany, Italy, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04393753. Inclusion in this directory is not an endorsement.